Jacqueline M. Wolfrum

Jacqueline M. Wolfrum

Auto-generated profile, based on publicly available information

Jacqueline M. Wolfrum

Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2023 in Computers & Chemical Engineering
Verified
Journal Article
Closed access
JRJinwook Rhyu
Jinwook Rhyu
DBDragana Bozinovski
Dragana Bozinovski
ADAlexis B. Dubs
Alexis B. Dubs
NMNaresh Mohan
Naresh Mohan
EBElizabeth M. Cummings Bende
Elizabeth M. Cummings Bende
RBRichard Braatz
Richard Braatz

13 April 2022 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
JHJiayi Huang
Jiayi Huang
LCLiang Cui
Liang Cui
MNMeenubharathi Natarajan
Meenubharathi Natarajan
PBPaul W. Barone
Paul W. Barone
JWJacqueline M. Wolfrum
Jacqueline M. Wolfrum
SSStacy L. Springs
Stacy L. Springs
Controlling microbial risks in cell therapy products (CTPs) is important for product safety. Here, we identified the nicotinic acid (NA) to nicotinamide (NAM) ratio as a biomarker that detects a broad spectrum of microbial contaminants in cell cultures. We separately added six different bacterial species into mesenchymal stromal cell and T cell culture and found that NA was uniquely present in these bacteria-contaminated CTPs due to the conversion from NAM by microbial nicotinamidases, which mammals lack. In cells inoculated with 1 × 104 CFUs/mL of different microorganisms, including USP defined organisms, the increase in NA to NAM ratio ranged from 72 to 15,000 times higher than the uncontaminated controls after 24 h. Importantly, only live microorganisms caused increases in this ratio. In cells inoculated with 18 CFUs/mL of Escherichia coli, 20 CFUs/mL of Bacillus subtilis, and 10 CFUs/mL of Candida albicans, significant increase of NA to NAM ratio was detected using LC-MS after 18.5, 12.5, and 24.5 h, respectively. In contrast, compendial sterility test required >24 h to detect the same amount of these three organisms. In conclusion, the NA to NAM ratio is a useful biomarker for detection of early-stage microbial contaminations in CTPs.


1 December 2024 in Advances in Physiology Education
Verified
Journal Article
Closed access
MYMingyu Yang
Mingyu Yang
FKFlora J. Keumurian
Flora J. Keumurian
CNCaleb Neufeld
Caleb Neufeld
ESElizabeth Skrip
Elizabeth Skrip
JDJohn Duguid
John Duguid
KVKrystyn J. Van Vliet
Krystyn J. Van Vliet
We assembled a team of university researchers and industry professionals to develop an online course on the principles and practice of cell therapy manufacturing. We believe that this course can serve as a model for how academia and industry can collaborate to create innovative, scalable training programs to meet the demands of the modern biotechnology workforce.

3 February 2026 in Computers & Chemical Engineering
Verified
Journal Article
Closed access
EAElia Arnese-Feffin
Elia Arnese-Feffin
JRJinwook Rhyu
Jinwook Rhyu
BSBenjamin T. Smith
Benjamin T. Smith
CCChris D. Castro
Chris D. Castro
JWJacqueline M. Wolfrum
Jacqueline M. Wolfrum
RBRichard Braatz
Richard Braatz

5 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
FDFrancesco Destro
Francesco Destro
PSPrasanna Srinivasan
Prasanna Srinivasan
JKJoshua M. Kanter
Joshua M. Kanter
CNCaleb Neufeld
Caleb Neufeld
JWJacqueline M. Wolfrum
Jacqueline M. Wolfrum
RBRichard Braatz
Richard Braatz
The demand for recombinant adeno-associated virus (rAAV) for gene therapy is expected to soon exceed current manufacturing capabilities, considering the expanding number of approved products and of pre-clinical and clinical stage studies. Current rAAV manufacturing processes have less-than-desired yields and produce a significant amount of empty capsids. Recently, FDA approved the first rAAV-based gene therapy product manufactured in the baculovirus expression vector system (BEVS). The BEVS technology, based on an invertebrate cell line derived from Spodoptera frugiperda , demonstrated scalable production of high volumetric titers of full capsids. In this work, we develop a mechanistic model describing the key extracellular and intracellular phenomena occurring during baculovirus infection and rAAV virion maturation in the BEVS. The predictions of the model show good agreement with experimental measurements reported in the literature on rAAV manufacturing in the BEVS, including for TwoBac, ThreeBac, and OneBac constructs. The model is successfully validated against measured concentrations of structural and non-structural protein components, and of vector genome. We carry out a model-based analysis of the process, to provide insights on potential bottlenecks that limit the formation of full capsids. The analysis suggests that vector genome amplification is the limiting step for rAAV production in TwoBac. In turn, vector genome amplification is limited by low Rep78 levels. For ThreeBac, low vector genome amplification dictated by Rep78 limitation appears even more severe than in TwoBac. Transgene expression in the insect cell during rAAV manufacturing is also found to negatively influence the final rAAV production yields.